Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma
Authors:
- Andrew D. NordenANAndrew D. Norden
- Keith L. LigonKLKeith L. Ligon
- Samantha N. HammondSHSamantha N. Hammond
- Alona MuzikanskyAMAlona Muzikansky
- David A. ReardonDRDavid A. Reardon
- Thomas J. KaleyTKThomas J. Kaley
- Tracy T. BatchelorTBTracy T. Batchelor
- Scott R. PlotkinSPScott R. Plotkin
- Jeffrey J. RaizerJRJeffrey J. Raizer
- Eric T. WongEWEric T. Wong
- Jan DrappatzJDJan Drappatz
- Glenn J. LesserGLGlenn J. Lesser
- 20 January 2015
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 84 (3) , 280-286
Abstract
Objective: A subset of meningiomas recur after surgery and radiation therapy, but no medical therapy for recurrent meningioma has proven effective. Methods: Pasireotide LAR is a long-acting somatostatin analog that may inhibit meningioma growth. This was a phase II trial in patients with histologically confirmed recurrent or progressive meningioma designed to evaluate whether pasireotide LAR prolongs progression-free survival at 6 months (PFS6). Patients were stratified by histology (atypical [World Health Organization grade 2] and malignant [grade 3] meningiomas in cohort A and benign [grade 3] in cohort B). Results: Eighteen patients were accrued in cohort A and 16 in cohort B. Cohort A had median age 59 years, median Karnofsky performance status 80, 17 (94%) had previous radiation therapy, and 11 (61%) showed high octreotide uptake. Cohort B had median age 52 years, median Karnofsky performance status 90, 11 (69%) had previous radiation therapy, and 12 (75%) showed high octreotide uptake. There were no radiographic responses to pasireotide LAR therapy in either cohort. Twelve patients (67%) in cohort A and 13 (81%) in cohort B achieved stable disease. In cohort A, PFS6 was 17% and median PFS 15 weeks (95% confidence interval: 8–20). In cohort B, PFS6 was 50% and median PFS 26 weeks (12–43). Treatment was well tolerated. Octreotide uptake and insulin-like growth factor–1 levels did not predict outcome. Expression of somatostatin receptor 3 predicted favorable PFS and overall survival. Conclusions: Pasireotide LAR has limited activity in recurrent meningiomas. The finding that somatostatin receptor 3 is associated with favorable outcomes warrants further investigation. Classification of evidence: This study provides Class IV evidence that in patients with recurrent or progressive meningioma, pasireotide LAR does not significantly increase the proportion of patients with PFS at 6 months.Keywords
This publication has 23 references indexed in Scilit:
- Monoclonal Antibodies against the Human Somatostatin Receptor Subtypes 1–5: Development and Immunohistochemical Application in Neuroendocrine TumorsNeuroendocrinology, 2011
- Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytomaNeuro-Oncology, 2011
- Response Assessment in Neuro-OncologyCurrent Oncology Reports, 2010
- SOM230 Inhibits Insulin-Like Growth Factor-I Action in Mammary Gland Development by Pituitary Independent Mechanism: Mediated through Somatostatin Subtype Receptor 3?Molecular Endocrinology, 2006
- The Oligodendroglial Lineage Marker OLIG2 Is Universally Expressed in Diffuse GliomasJournal of Neuropathology & Experimental Neurology, 2004
- Expression of Somatostatin Receptor mRNA in Human Meningiomas and their Implication in in vitro Antiproliferative ActivityJournal of Neuro-Oncology, 2004
- SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profileEuropean Journal of Endocrinology, 2002
- Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A.2000
- Somatostatin and Its Receptor FamilyFrontiers in Neuroendocrinology, 1999
- Response criteria for phase II studies of supratentorial malignant glioma.Journal of Clinical Oncology, 1990